INTRODUCTION: In children with cancer a well-known risk factor for cardiotoxicity is a high cumulative dose of anthracyclines, but little is known about cardiac function in low-dose anthracycline-treated survivors. Also, it is unclear if a safe anthracycline-dose exists at all. PATIENTS AND METHODS: Cardiac function was assessed in 23 long-term ALL-survivors with a median follow-up of 22 years (range 19.5-24.5) post-treatment. Age at diagnosis and current age were 5.0 (2.0-14.0) and 29.0 (24.0-39.0) years. All 23 survivors were treated according to DCLSG protocol ALL-5, including 18-25 Gy cranial irradiation. Thirteen of them received 4 x 25 mg/m(2) daunorubicin by randomization. Cardiac evaluation included blood pressure measurement, echocardiography, and (24 h-) electrocardiogram. Results were compared with an earlier assessment at median 12 years post-treatment. RESULTS: None of the survivors had cardiac abnormalities. Cardiac status of daunorubicin-treated survivors showed no deterioration compared with the previous assessment in 1995. CONCLUSION AND IMPLICATION FOR CANCER SURVIVORS: After prolonged follow-up (more than 20 years post-treatment), ALL-survivors treated with low dose daunorubicin had no clinical relevant deterioration of cardiac function.
INTRODUCTION: In children with cancer a well-known risk factor for cardiotoxicity is a high cumulative dose of anthracyclines, but little is known about cardiac function in low-dose anthracycline-treated survivors. Also, it is unclear if a safe anthracycline-dose exists at all. PATIENTS AND METHODS: Cardiac function was assessed in 23 long-term ALL-survivors with a median follow-up of 22 years (range 19.5-24.5) post-treatment. Age at diagnosis and current age were 5.0 (2.0-14.0) and 29.0 (24.0-39.0) years. All 23 survivors were treated according to DCLSG protocol ALL-5, including 18-25 Gy cranial irradiation. Thirteen of them received 4 x 25 mg/m(2) daunorubicin by randomization. Cardiac evaluation included blood pressure measurement, echocardiography, and (24 h-) electrocardiogram. Results were compared with an earlier assessment at median 12 years post-treatment. RESULTS: None of the survivors had cardiac abnormalities. Cardiac status of daunorubicin-treated survivors showed no deterioration compared with the previous assessment in 1995. CONCLUSION AND IMPLICATION FOR CANCER SURVIVORS: After prolonged follow-up (more than 20 years post-treatment), ALL-survivors treated with low dose daunorubicin had no clinical relevant deterioration of cardiac function.
Authors: Melvin D Cheitlin; William F Armstrong; Gerard P Aurigemma; George A Beller; Fredrick Z Bierman; Jack L Davis; Pamela S Douglas; David P Faxon; Linda D Gillam; Thomas R Kimball; William G Kussmaul; Alan S Pearlman; John T Philbrick; Harry Rakowski; Daniel M Thys; Elliott M Antman; Sidney C Smith; Joseph S Alpert; Gabriel Gregoratos; Jeffrey L Anderson; Loren F Hiratzka; David P Faxon; Sharon Ann Hunt; Valentin Fuster; Alice K Jacobs; Raymond J Gibbons; Richard O Russell Journal: J Am Soc Echocardiogr Date: 2003-10 Impact factor: 5.251
Authors: K Nysom; K Holm; S R Lipsitz; S M Mone; S D Colan; E J Orav; S E Sallan; J H Olsen; H Hertz; J R Jacobsen; S E Lipshultz Journal: J Clin Oncol Date: 1998-02 Impact factor: 44.544
Authors: N B Schiller; P M Shah; M Crawford; A DeMaria; R Devereux; H Feigenbaum; H Gutgesell; N Reichek; D Sahn; I Schnittger Journal: J Am Soc Echocardiogr Date: 1989 Sep-Oct Impact factor: 5.251
Authors: G Tjeerdsma; M T Meinardi; W T van Der Graaf; M P van Den Berg; N H Mulder; H J Crijns; E G de Vries; D J van Veldhuisen Journal: Heart Date: 1999-04 Impact factor: 5.994
Authors: C A J Brouwer; J A Gietema; M P van den Berg; M T E Bink-Boelkens; N J Elzenga; J Haaksma; W A Kamps; J M Vonk; E G E de Vries; A Postma Journal: Ann Oncol Date: 2006-07-20 Impact factor: 32.976
Authors: Vladimír Kincl; Roman Panovský; Tomáš Kepák; Viera Bajčiová; Veronika Bednárová; Lukáš Opatřil; Jan Máchal Journal: Cancer Med Date: 2022-02-15 Impact factor: 4.711